Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | TYK2 | P29597 | 3/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | LSS | P48449 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1330040 | 0.86 | AXL (0.46) | DGAT1AXLKCNH2 | |
| SCHEMBL1330672 | 0.75 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL11976878 | 0.71 | DGAT1 (0.43) | DGAT1TYRO3 | |
| SCHEMBL1329995 | 0.70 | DGAT1 (0.43) | DGAT1TYRO3 | |
| SCHEMBL28923118 | 0.70 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL24159819 | 0.69 | DGAT1 (0.41) | DGAT1TYRO3 | |
| SCHEMBL19462084 | 0.69 | KIT (0.37) | KCNH2 | |
| SCHEMBL29935301 | 0.69 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL24809118 | 0.68 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL16024590 | 0.68 | DGAT1 (0.38) | DGAT1BCHECNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293738-B2 | Indazole inhibitors of kinase | ABBOTT LABORATORIES (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110281868-A1 | INDAZOLE INHIBITORS OF KINASE | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281868-A1 | INDAZOLE INHIBITORS OF KINASE | AURKA, AURKC, AURKB | JAK2 260/4885JAK3 114/4885JAK1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.